A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
Evan M. Hersh, Steven J O'Day, John D. Powderly et al. · Investigational New Drugs · 2010
Cited by 307 works. doi:10.1007/s10637-009-9376-8
Authors
- Evan M. Hersh
- Steven J O'Day
- John D. Powderly
- Khuda Dad Khan
- Anna C. Pavlick
- Lee D. Cranmer
- Wolfram E. Samlowski
- Geoffrey M. Nichol
- Michael Jay Yellin
- Jeffrey S. Weber
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials